Sho Yamazaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sho Yamazaki has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Akimasa Someya
Affiliation Department of Host Defense and Biochemical Research, Juntendo University, Graduate School of Medicine, Bunkyo-Ku, Tokyo 113–8421, Japan
1 shared publication - Isao Nagaoka
Faculty of Medical Science, Juntendo University, Urayasu, Japan
1 shared publication - Keisuke Yamaguchi
Department of Anesthesiology, Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan
1 shared publication - Masakazu Hayashida
Department of Anesthesiology and Pain Medicine, Juntendo University School of Medicine, Tokyo, Japan
1 shared publication
Latest Publications
- Open Access
- 3 September 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (17) , 10096
Anti-Inflammatory Action of Dexmedetomidine on Human Microglial Cells
Neuroinflammation, where inflammatory cytokines are produced in excess, contributes to the pathogenesis of delirium. Microglial cells play a central role in neuroinflammation by producing and releasing inflammatory cytokines in response to infection, tissue damage and neurodegeneration. Dexmedetomidine (DEX) is a sedative, which reduces the incidence of delirium. Thus, we hypothesized that DEX may alleviate delirium by exhibiting anti-inflammatory action on microglia. In the present study, we investigated the anti-inflammatory action of DEX on human microglial HMC3 cells. The results indicated that DEX partially suppressed the IL-6 and IL-8 production by lipopolysaccharide (LPS)-stimulated HMC3 cells as well as the phosphorylation of p38 MAPK and IκB and the translocation of NF-κB. Furthermore, DEX substantially suppressed IL-6 and IL-8 production by unstimulated HMC3 cells as wells as the phosphorylation of p38 MAPK and IκB and the translocation of NF-κB. These observations suggest that DEX exhibits anti-inflammatory action on not only LPS-stimulated but also unstimulated microglial cells via the suppression of inflammatory signaling and cytokine production.
- 3 September 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (17) , 10096
Open AccessAnti-Inflammatory Action of Dexmedetomidine on Human Microglial Cells
Neuroinflammation, where inflammatory cytokines are produced in excess, contributes to the pathogenesis of delirium. Microglial cells play a central role in neuroinflammation by producing and releasing inflammatory cytokines in response to infection, tissue damage and neurodegeneration. Dexmedetomidine (DEX) is a sedative, which reduces the incidence of delirium. Thus, we hypothesized that DEX may alleviate delirium by exhibiting anti-inflammatory action on microglia. In the present study, we investigated the anti-inflammatory action of DEX on human microglial HMC3 cells. The results indicated that DEX partially suppressed the IL-6 and IL-8 production by lipopolysaccharide (LPS)-stimulated HMC3 cells as well as the phosphorylation of p38 MAPK and IκB and the translocation of NF-κB. Furthermore, DEX substantially suppressed IL-6 and IL-8 production by unstimulated HMC3 cells as wells as the phosphorylation of p38 MAPK and IκB and the translocation of NF-κB. These observations suggest that DEX exhibits anti-inflammatory action on not only LPS-stimulated but also unstimulated microglial cells via the suppression of inflammatory signaling and cytokine production.